Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Jonathan Cohen, Alison Palumbo, Jason Wing, Michael C. Heinrich

    Research output: Contribution to journalLetterpeer-review

    Original languageEnglish (US)
    Pages (from-to)2511-2514
    Number of pages4
    JournalLeukemia and Lymphoma
    Volume61
    Issue number10
    DOIs
    StatePublished - Aug 23 2020

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Cite this